Fusion Antibodies (LSE:FAB) EV-to-EBITDA : -1.13 (As of Apr. 25, 2024)

Fusion Antibodies EV-to-EBITDA Chart

Fusion Antibodies Annual Data
	Trend	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23
EV-to-EBITDA		Get a 7-Day Free Trial				-4.18	-46.01	-70.96	-23.79	-3.99

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EV-to-EBITDA	Get a 7-Day Free Trial											-	-23.79	-	-3.99	-

Competitive Comparison of Fusion Antibodies's EV-to-EBITDA

For the Biotechnology subindustry, Fusion Antibodies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fusion Antibodies's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's EV-to-EBITDA falls into.

Fusion Antibodies EV-to-EBITDA Calculation

Fusion Antibodies's EV-to-EBITDA for today is calculated as:

Fusion Antibodies's current Enterprise Value is £3.14 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusion Antibodies's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was £-2.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fusion Antibodies  (LSE:FAB) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Fusion Antibodies's PE Ratio for today is calculated as:

Fusion Antibodies's share price for today is £0.0375.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusion Antibodies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.086.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Fusion Antibodies EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies (LSE:FAB) Business Description